LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD ...

Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be ...

Dr. Nimesh A. Patel reveals key findings on pegcetacoplan and anti-VEGF treatments for geographic atrophy and neovascular AMD ...

Discover new safety insights on Syfovre for geographic atrophy treatment, as Roger A. Goldberg highlights promising long-term data at ASRS 2025.

Treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy are under review.

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Jay Chhablani, MD, presented the phase 1/2 clinical trial data for OCU410, at the 2025 annual meeting of the American Society of Retina Specialists.

Researchers reported efficacy and safety data through 48 months of continuous pegcetacoplan treatment across OAKS, DERBY and ...